Development of a World Health Organization International Reference Panel for different genotypes of hepatitis E virus for nucleic acid amplification testing. by Baylis, Sally A. et al.
Contents lists available at ScienceDirect
Journal of Clinical Virology
journal homepage: www.elsevier.com/locate/jcv
Development of a World Health Organization International Reference Panel for
different genotypes of hepatitis E virus for nucleic acid amplification testing
Sally A. Baylisa,⁎, Kay-Martin O. Hanschmanna, Keiji Matsubayashib, Hidekatsu Sakatac,
Anne-Marie Roque-Afonsod, Marco Kaisere, Victor M. Cormanf,g, Saleem Kamilih,
Rakesh Aggarwalb,i,1, Nirupma Trehanpatij, Thomas Gärtnerk, Emma C. Thomsonl,
Christopher A. Davisl, Ana da Silva Filipel, Tamer T. Abdelrahmanl,m, Johannes Blümela,
Eriko Teraon, the HEV collaborative study group2
a Paul-Ehrlich-Institut, Langen, Germany
b Central Blood Institute, Japanese Red Cross Society, Tokyo, Japan
c Japanese Red Cross Hokkaido Block Blood Center, Sapporo, Japan
d Virologie AP-HP Hôpital Paul Brousse, Villejuif, France
eGenExpress Gesellschaft für Proteindesign mbH, Berlin, Germany
f Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology,
Berlin, Germany
gGerman Centre for Infection Research (DZIF), Berlin, Germany
hDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, USA
i Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
j Institute of Liver and Biliary Sciences, New Delhi, India
kOctapharma, Frankfurt am Main, Germany
lUniversity of Glasgow Centre for Virus Research, UK
mMicrobiology Department, King Fahad Medical City, Riyadh, Saudi Arabia
n European Directorate for the Quality of Medicines & HealthCare, Strasbourg, France
A R T I C L E I N F O
Keywords:
Hepatitis E virus
HEV
NAT
NAAT
Standardization
Genotype
World Health Organization
A B S T R A C T
Background: Globally, hepatitis E virus (HEV) is a major cause of acute viral hepatitis. Epidemiology and clinical
presentation of hepatitis E vary greatly by location and are affected by the HEV genotype. Nucleic acid am-
plification technique (NAT)-based assays are important for the detection of acute HEV infection as well for
monitoring chronic cases of hepatitis E.
Objectives: The aim of the study was to evaluate a panel of samples containing different genotypes of HEV for use
in nucleic NAT-based assays.
Study design: The panel of samples comprises eleven different members including HEV genotype 1a (2 strains),
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1e, 2a, 3b, 3c, 3e, 3f, 4c, 4g as well as a human isolate related to rabbit HEV. Each laboratory assayed the panel
members directly against the 1st World Health Organization (WHO) International Standard (IS) for HEV RNA
(6329/10) which is based upon a genotype 3 a strain.
Results: The samples for evaluation were distributed to 24 laboratories from 14 different countries and assayed
on three separate days. Of these, 23 participating laboratories returned a total of 32 sets of data; 17 from
quantitative assays and 15 from qualitative assays. The assays used consisted of a mixture of in-house developed
and commercially available assays. The results showed that all samples were detected consistently by the ma-
jority of participants, although in some cases, some samples were detected less efficiently.
Conclusions: Based on the results of the collaborative study the panel (code number 8578/13) was established as
the “1st International Reference Panel (IRP) for all HEV genotypes for NAT-based assays” by the WHO Expert
Committee on Biological Standardization. This IRP will be important for assay validation and ensuring adequate
detection of different genotypes and clinically important sub-genotypes of HEV.
1. Background
Worldwide, hepatitis E virus (HEV, species Orthohepevirus A,
Hepeviridae) is a major cause of acute hepatitis. Diagnosis of acute he-
patitis E relies upon detection of HEV RNA by nucleic acid amplification
techniques (NAT or NAAT) [1]. The lack of assay standardization [2]
led to the development and the establishment of the 1st World Health
Organization (WHO) International Standard (IS) for HEV RNA (code
number 6329/10) [3]. The WHO IS is a measurement standard with an
internationally agreed concentration. The introduction of this reference
material has facilitated the comparison of quantitative HEV RNA assays
and determination of analytical sensitivities by reporting of results in
international units (IU) in line with other WHO ISs [4]. This WHO IS
represents an HEV sub-genotype 3a HEV strain from a Japanese blood
donor diluted in HEV RNA negative human plasma.
A member of the Hepeviridae family of viruses, HEV is represented by a
single serotype with four main genotypes infecting humans [5]. HEV gen-
otypes 1 and 2 can be found in humans, whilst genotypes 3 and 4 are found
in both humans as well as a range of animal species, particularly pigs [1].
The geographical distribution of HEV genotypes is complex. HEV genotype
1 consists of strains circulating in Africa and Asia. Genotype 2 has been
found in Mexico and in some African countries. Genotype 3 is widely dis-
tributed, mainly being reported in the USA, Europe and Japan and more
recently South America. Genotype 4 tends to be restricted to China, Japan
and East Asia. However, genotype 1 viruses, and more recently genotype 4
viruses, have also occasionally been found in patients in Europe, North
America and elsewhere after travelling to endemic areas and are mainly
imported cases. Epidemics and sporadic cases of hepatitis E occur in areas of
endemicity (genotypes 1, 2 and 4); more isolated clinical cases are diag-
nosed mostly among asymptomatic seropositive residents in developed
countries (mainly genotype 3). Chronic infection, almost exclusively with
genotype 3 HEV, occurs in immunocompromised patients and, more rarely,
those with HIV infection [1]. At the nucleotide level, HEV strains, more
rarely, can vary by ∼26% between genotypes and up to ∼15% between
sub-genotypes. Given the levels of diversity and the importance of the
epidemic strains in terms of the global disease burden of hepatitis E, the
preparation of an International Reference Panel (IRP) panel for HEV gen-
otypes was endorsed by the WHO Expert Committee of Biological Stan-
dardization. Such panels are important to help ensure consistent detection
of viral variants and are complementary resources to WHO ISs.
Here, we present the results of a study evaluating the candidate panel
which was evaluated simultaneously with a biological reference prepara-
tion (BRP) prepared on behalf of the Biological Standardisation Programme
of the European Directorate for the Quality of Medicines & HealthCare
(EDQM), Council of Europe and the EU Commission. The calibration of the
genotype 3f [6] BRP in IU/ml, used as a control for the testing of HEV RNA
in solvent/detergent-treated plasma is described elsewhere [7].
2. Study design
2.1. Preparation of materials
The HEV strains selected for the preparation of the panel are shown
in Table 1. The strains were derived from a mixture of HEV RNA-po-
sitive plasma and stool samples. The strains were selected to cover the
four main genotypes of HEV infecting humans as well as clinically
Table 1
Details of HEV strains used in the development of the panel.
Code Genotype Strain Origin Sample Type Anti-HEV - IgM/IgG Accession number
8567/13 1a India Plasma n.d. n.a.#
8568/13 s 1a Kol-15 India Stool n.a. n.a.#
8569/13 1e Sudan Plasma +/- n.a.#
8570/13 3b JRC-HE3 Japan Plasma +/- AB630971
8571/13 3c Oct 8 Sweden Plasma -/- JN995569#
8572/13 3e Oct 3 Germany Plasma -/- JN995564#
8573/13 3f* Oct 12 Sweden Plasma -/- JN995573#
8574/13 s 3 (rabbit) France Stool n.a. MG211750
8575/13 4c HRC-HE15 Japan Plasma -/- LC387631
8576/13 4 g HRC-HE58 Japan Plasma -/- LC387632
8577/13 2 Mex 14 Mexico Stool n.a. KX578717
8577/13 s 2 Mex 14 Mexico Stool n.a. KX578717
n.d. not determined
n.a. not applicable
N.B. XXXX/13 s, denotes panel members derived from stool samples
*3f – tentatively assigned as 3 l using the HEVnet criteria: https://www.rivm.nl/en/Topics/H/HEVNet
Sample 8577/13 was not formulated using stabilizers and contains the same strain of HEV as sample 8577/13 s. The concentration of HEV in the two samples is
different.
#Partial sequence data included in original study report for 1a and 1e http://apps.who.int/iris/bitstream/handle/10665/197775/
WHO_BS_2015.2264_eng.pdf;jsessionid=31DC19F99562D2722A9B88594D83AF51?sequence=1, whole genome sequencing of panel has been performed
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important sub-genotypes prevalent in different regions.
For panel preparation, the HEV RNA-positive samples were diluted
using pooled citrated human plasma which tested negative for HBV,
HCV and HIV-1/2 using the cobas® TaqScreen MPX Test v 2.0 (Roche
Molecular Systems Inc., Branchburg, NJ, USA) and was negative for
HEV RNA (testing described below) and anti-HEV IgM and anti-HEV
IgG by enzyme immunoassays (Wantai, Beijing, China). All HEV RNA-
positive plasma samples used in the preparation of the candidate panel
were tested and found negative for the presence of HBV, HCV and HIV-
1/2 using the cobas® TaqScreen MPX Test v 2.0. In the case of 8567/13
and 8569/13, the samples were diluted 1:500 prior to testing.
Stool samples were diluted in Dulbecco's Modified Eagle's Medium,
filtered through 1 μM and then 0.2 μM filters and mixed with an equal
volume of negative plasma (described above) and frozen at −80 °C
prior to processing. The stool samples were further diluted in plasma
prior to lyophilization, and in order to stabilize the HEV strains, tre-
halose and magnesium chloride were added at final concentrations of
5% and 150mM, respectively. The formulation of the final matrix was
found not to inhibit a range of PCR and transcription-based NAT assays.
To confirm the (sub-)genotype, sequencing and phylogenetic ana-
lysis was performed in the HEV open reading frame 1 region (ORF1) by
a highly sensitive and broadly reactive nested reverse transcription-PCR
(RT-PCR) assay amplifying a 283-nucleotide fragment of the RNA-de-
pendent RNA-polymerase (RdRP) gene as described previously [8].
Furthermore, for 11 of the 13 complete HEV genomes information was
obtained by next generation sequencing (manuscript in preparation) or
was available from previous studies (Table 1). No discrepancies be-
tween the RdRP sequences and the complete genome sequences were
observed. Therefore, complete genome data was used for phylogenetic
reconstructions, using a GTR nucleotide substitution model and a
Maximum Likelihood algorithm with 1000 bootstrap in Geneious 11
(http://www.geneious.com).
Filling and lyophilization of 0.5 ml volumes of the bulk samples was
as previously described [3]. Vials were stored at −20 °C.
2.2. Collaborative study
In the collaborative study, the candidate IRP members were eval-
uated for potency in parallel with the WHO IS.
Study materials, sufficient for three assay runs, were shipped to
participants on dry ice and then stored at ≤−20 °C. Participants re-
ceived 12 samples representing different HEV (sub-) genotypes (in-
cluding one strain prepared in two different types of matrices together
with the WHO IS (Table 1). Of the samples, eleven were candidate IRP
members and one further sample (8577/13) was included as a matrix
control for candidate IRP member 8577/13 s. Both 8577/13 and 8577/
13 s were formulated with the same strain, however, they were for-
mulated in plasma and plasma containing stabilizers, respectively.
Participants were requested to perform testing using their routine HEV
RNA assays using fresh vials of each sample for each assay run. Samples
reconstitution was performed using 0.5 ml molecular biology grade
water per vial with agitation for ∼20minutes prior to use.
For quantitative tests, participants were requested to use the WHO
IS 6329/10 to create a standard curve (testing the IS neat and by three
ten-fold serial dilutions i.e. 250,000 IU/ml (neat) to 250 IU/ml) and
data reported directly in IU/ml. The panel of samples were tested
without prior dilution.
For qualitative assays, participants were requested to assay each
sample alongside the IS. In the first assay, a series of one log10 dilution
steps, were used to obtain estimates of end-points. Half-log10 dilutions
around the end-point were performed for the subsequent two assay
runs. Results were reported as either positive or negative. Dilutions
were prepared using diluent in regular use by the respective labora-
tories e.g. HEV-negative plasma. All participants used plasma as a di-
luent with the exception of Laboratory 3 where water was used.
Relevant information (e.g. CT values for the respective dilutions
where real time PCR methods were used or signal to cut-off (S/Co)
values - e.g. for transcription-mediated assays) were reported by par-
ticipants using electronic reporting sheets.
2.3. Statistical methods
2.3.1. Quantitative assays
Potency estimates determined for each sample relative to the WHO
IS (measured in log10 IU/ml) based on quantitative data were derived
using a mixed linear model with random factors laboratory and assay
run.
2.3.2. Qualitative assays
For qualitative data analysis, results from all the three assays for
each laboratory were pooled to give the number of positives out of the
total number tested at each dilution. Assuming that a single ‘detectable
unit’ will give a positive result, with the probability of a positive result
following a Poisson distribution, the EC63 (the dilution at which 63% of
the samples are expected to be positive) was chosen as the end-point.
For each dilution series, this end-point was estimated by means of a
probit analysis. Within the same evaluation, relative potencies were
also estimated.
For assays reporting CT values, these were evaluated for both qua-
litative and quantitative methods (relative to WHO IS) using a parallel
line model for each laboratory and assay run, as well as combined for
all evaluable (i.e. valid) assay runs.
Qualitative sample cut-off values from Laboratory 5 and 7 were
evaluated by means of a sigmoid dose-response model. Samples with
less than 3 dose values and/or non-linear or non-parallel behaviour
were excluded from the analysis.
Parallel line and sigmoid evaluation model as well as a combination
of assays were performed according to methods as described in chapter
5.3, “Statistical analysis of results of biological assays and tests”, of the
Ph. Eur. The statistical analysis was performed with SAS®/STAT soft-
ware, version 9.4, SAS System for Windows, and CombiStats, version
5.0, EDQM, Council of Europe.
2.4. Stability studies
Vials of the candidate panel samples were stored at −20 °C (the
normal storage temperature) and −80 °C (to provide a baseline). For
the accelerated thermal degradation, vials were incubated at +4 °C,
+20 °C and +37 °C for up to 6 months. After incubation at the re-
spective temperatures, the contents of the vials were reconstituted in
0.5 ml of nuclease free water and analysed by real-time PCR as pre-
viously described [3].
3. Results
3.1. Data received
Data were received from 23 participating laboratories. A total of 32
data sets were returned; 17 from quantitative assays and 15 from
qualitative assays. Some laboratories reported results for more than one
type of assay. The types of methods used by the participants are listed in
Table 2 [9–15]. The majority of assays designs are based on primers
targeting HEV ORF2/3 region.
Phylogenetic analysis of the panel strains, the WHO IS, and all re-
ference Orthohepevirus A strains and subtypes defined by Smith et al.
[16], are shown in Fig. 1.
The different HEV genotypes and sub-genotypes were detected by
all participants, with a single exception – Laboratory 12 was unable to
detect sample 8567/13 (HEV genotype 1a) in any of the three assay
runs. In some cases, differences in the efficiency of detection were ob-
served for some of the candidate panel members. Some of the other
samples were inconsistently detected by Laboratory 12. Laboratory 6
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reported inhibition of some of the undiluted samples, including some of
the stool-derived materials; however this was not consistent across
assay runs. Laboratory 6 used the NucliSENS easyMag (bioMérieux)
extraction platform and other laboratories using this system did not
report inhibition of any of the samples and it is possible that inhibition
may have been due to the high proportion of extracted nucleic acid
used in the amplification/detection reaction.
3.2. Quantitative assay results
The individual laboratory mean estimates (log10 IU/ml) for the
candidate panel samples assayed directly against the WHO IS 6329/10
are shown in Tables S1a and S1b. The relative variation of the in-
dividual laboratory estimates is illustrated by the box-and-whisker plots
in Figure S1. Greater variation was observed with the genotypes 1, 2
and 4, whereas better agreement was observed for the genotype 3
strains. The genotype 3b strain (sample 8570/13) had been evaluated in
previous studies [2,3] and was established as the first HEV RNA Na-
tional Standard in Japan.
The laboratory mean absolute estimates of IU/ml (log10) are shown
in histogram form in Fig. 2. For the quantitative assay results, each
white box represents the mean estimate from an individual laboratory,
and is labelled with the laboratory code number. In general, good
agreement was observed between the laboratories performing quanti-
tative assays. The overall means from all laboratories for the quanti-
tative assays are shown in Table S2.
3.3. Qualitative assay results
The individual laboratory relative potency estimates (log10 IU/ml),
for the candidate panel samples assayed in parallel against the WHO IS
6329/10 are shown in Tables S3A and S3b (based upon end-point
dilution analysis). The overall means from all laboratories for the
qualitative end-point dilution assays are shown in Table S4. In addition,
mean estimates were also evaluated by analysis of CT and S/Co values
for the qualitative assays (Tables S5a and S5b). The relative variation of
the individual laboratory estimates for the qualitative assays is illu-
strated by the box-and-whisker plots in Figure S2. The overall means
from all laboratories for the analysis of CT and S/Co values for the
qualitative assays are shown in Table S6.
The qualitative assays are much more variable than the quantitative
assays, reflecting the different sensitivities of the assays performed in
different participating laboratories. The potencies of the panel samples
for the qualitative assay results are shown in Fig. 2, each dark grey box
represents the mean estimate from an individual laboratory, and is la-
belled with the laboratory code number – these data represent the end-
point dilution analysis; values determined by analysis of the CT values
are shown in the black boxes. In general, the results from the qualitative
assay are in good agreement with those of the quantitative assays.
3.4. Determination of overall laboratory means – combined qualitative and
quantitative results
The overall mean values, including range and standard deviations,
for the candidate panel samples are shown in Table 3. The respective
overall means are a combination of the quantitative data (IU/ml), the
qualitative data (based on end-point dilution); potencies determined by
analysis of reported CT values or S/Co values from the qualitative assays
for the panel samples relative to the WHO IS.
In general, the overall means are in line with the expected range of
results that had been previously communicated to the participants (data
not shown). No unitage was assigned to the panel samples, in keeping with
other such panels and potencies are merely for guidance for users [4].
Table 2
Assay protocols used by participants.
Laboratory code Assay typea Extraction method NAT method Reference
1 Quant. High Pure Viral Nucleic Acid Kit Large Volume (Roche) Real-time RT-PCR (RealStar® HEV RT-PCR Kit 1.0, altona Diagnostics)
2 Quant. QIAamp Viral RNA Mini Kit (Qiagen) Real-time RT-PCR (RealStar® HEV RT-PCR Kit 1.0, altona Diagnostics)
3A/3B Quant./Qual. NucliSENS® easyMag® (bioMérieux) Real-time RT-PCR (HepatitisE@ceeramTools™)
4 Quant. EZ1 Virus Mini Kit v2.0 (Qiagen) Real-time RT-PCR (TaqMan) 9
5 Qual. Automated proprietary magnetic target capture method
– Procleix Panther System
Transcription mediated amplification and hybridization protection
assay (Procleix HEV Assay, Hologic Inc.)
6A/B Quant./Qual. NucliSENS® easyMag® (bioMérieux) Real-time RT-PCR (RealStar® HEV RT-PCR Kit 1.0, altona Diagnostics)
6C/D Quant./Qual. chemagic Viral DNA/RNA Kit (PerkinElmer) Real-time RT-PCR (RealStar® HEV RT-PCR Kit 1.0, altona Diagnostics)
6E Qual. NucliSENS® easyMag® (bioMérieux) ampliCube HEV 2.0 (Mikrogen GmbH)
6F Qual. chemagic Viral DNA/RNA Kit (PerkinElmer) ampliCube HEV 2.0 (Mikrogen GmbH)
7 Qual. Automated proprietary magnetic target capture method
– Procleix Panther System
Transcription mediated amplification and hybridization protection
assay (Procleix HEV Assay; Hologic Inc.)
8 Qual. QIAamp MinElute Virus Spin Kit/QIAcube (Qiagen) Real-time RT-PCR (RealStar® HEV RT-PCR Kit 1.0, altona Diagnostics)
9 Quant. QIAsymphony DSP Virus/Pathogen Mini Kit (Qiagen) Real-time RT-PCR (TaqMan)
10 Quant. QIAamp MinElute Virus Spin Kit (Qiagen) Real-time RT-PCR (TaqMan) 10
11 Qual. QIAamp Viral RNA Mini Kit (Qiagen) Real-time RT-PCR (RealStar® HEV RT-PCR Kit 1.0, altona Diagnostics)
12 Quant. SMI-TEST EX-R&D (Medical Biological Laboratories Co.,
Ltd.)
Real-time RT-PCR (TaqMan) 11
13 Qual. QIAamp Viral RNA Mini Kit (Qiagen) Real-time RT-PCR (TaqMan)
14 Qual. Roche cobas® 6800/8800 Real-time RT-PCR (cobas® HEV, Roche Molecular Systems)
15 Quant. QIAamp MinElute Virus Spin Kit/QIAcube (Qiagen) Real-time RT-PCR (TaqMan)
16 Quant. MagNA Pure 96 Viral NA Large Volume Kit (Roche) Real-time RT-PCR (TaqMan) 12
17 Quant. MagNA Pure LC (Roche) Real-time RT-PCR (SYBR Green) 13
18 Quant. MagNA Pure 96 Viral NA Large Volume Kit (Roche) Real-time RT-PCR (TaqMan) 13, 14
19A/B Quant./Qual. NucliSENS® easyMag® (bioMérieux) Real-time RT-PCR (TaqMan) 15
20 Qual. NucliSENS® easyMag® (bioMérieux) Real-time RT-PCR (TaqMan)
21A/B Quant./Qual. GenMag Viral DNA/RNA Kit (GenMagBio) Real-time RT-PCR (TaqMan) 13
22 Qual. QIAamp Viral RNA Mini Kit (Qiagen) Real-time RT-PCR (Diagnostic kit hepatitis E virus RNA, Beijing
Kinghawk Pharmaceutical Co., Ltd.)
15
23A Quant. High Pure Viral Nucleic Acid Kit (Roche) Real-time RT-PCR (RealStar® HEV RT-PCR Kit 1.0, altona Diagnostics)
23C Quant. High Pure Viral Nucleic Acid Kit (Roche) Real-time RT-PCR (TaqMan) 13
a Data returned in qualitative (Qual.) or quantitative (Quant.) format. The altona Diagnostics assay was used both qualitatively (end-point dilution) and quan-
titatively against the WHO IS.
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3.5. Stability studies
The plasma-derived viruses showed good stability comparable to
that of the WHO IS when stored at elevated temperatures. However, in
initial studies, it was found that all stool derived viruses (genotype 1a,
1e and 2a), diluted in plasma were unstable at 37 °C, such that in under
1 week, HEV RNA was barely detectable – Figure S3 (data shown for
genotypes 1e and 2a). Lyophilization of plasma spiked with the same 3a
HEV strain used to establish the WHO IS, treated with detergent (Triton
X-100, 0.5% final concentration), demonstrated very similar inactiva-
tion kinetics to the HEV stool samples, this was not the case when no
detergent was added (Figure S3). Because of the lack of stability at
elevated temperatures, different concentrations/combinations of stabi-
lizing agents were added to determine which formulation gave the best
overall stability. It was found that trehalose and magnesium chloride
added at final concentrations of 5% and 150mM, respectively gave the
best overall stability. Figure S4 demonstrates the difference on HEV
genotype 2a RNA stability when formulated in the presence/absence of
stabilizers at elevated temperature when compared to storage at
−20 °C or baseline (-80°). The two stabilizers were most effective when
used in combination than when used separately and lower concentra-
tions were not as effective as those used in the final formulation.
For the real time stability studies, there was no loss of signal ob-
served for any panel member under normal storage conditions i.e.
−20 °C compared to baseline samples stored at −80 °C for ∼3.5 years
(data not shown). For the accelerated degradation studies, in the case of
the individual panel members there was a drop of between 0.0-0.5 log10
IU/ml (Tables S7a and S7b) after storage of the samples at +20 °C for 3
to 6 months; greater loss of titre was observed at +37 °C.
4. Discussion and conclusion
In this study, a wide range of quantitative and qualitative assay
formats were used to evaluate the candidate HEV RNA genotype panel
of samples in parallel with the WHO IS. Approximately half of the as-
says had been developed in-house with the rest being commercially
available, this is in contrast to the initial study to evaluate laboratory
performance where only one commercial assay was included [2] and
Fig. 1. Maximum-likelihood phylogeny of the complete coding
sequences of reference Orthohepevirus A strains and genotype (gt)
subtypes defined by Smith et al. [16], and HEV strains used in this
study (given in red), the WHO IS strain is given in blue. Taxon
names of all reference sequences include genotype, subtype (“x” if
not available), and GenBank accession (For interpretation of the
references to colour in this figure legend, the reader is referred to
the web version of this article).
Black circles at nodes indicate bootstrap supports of> 90% and
white circles> 75% (1,000 replicates). For the two viruses
marked with an asterisk only a sequence fragment of ORF1 was
available for analysis.
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Fig. 2. Potency in log10 IU/ml based on quantitative methods (white boxes); potency based on analysis of CT values from qualitative methods (black boxes); potency
based on qualitative, end-point dilution analysis (dark grey boxes); potency based on analysis of CT values from quantitative methods.
Values determined by Laboratory 23A were based on a single assay run, the samples were inconsistently detected.
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the study to establish the WHO IS where all the assays had been de-
veloped in-house [2,3]. With a single exception, all participants were
able to detect all the different HEV genotypes and sub-genotypes in-
cluded in the panel. One in-house assay, used by a single laboratory,
failed to detect 8567/13, a genotype 1a HEV strain which had the
lowest titre of any of the panel members; this may be due to a lack of
assay sensitivity for example, due to suboptimal extraction efficiency or
possibly due to primer design.
There were noticeable differences in the potencies for some of the
samples – particularly genotype 2 for which there are very few reported
sequences. In contrast, the potencies reported for the genotype 3 strains
were less variable and reflect the availability of a large number of se-
quences and evaluation of several of these strains in previous studies
[2,3].
The sample 8577/13 (HEV genotype 2a) was included as a matrix
control. Because of the instability of 8577/13 at ambient temperature,
the formulation of the sample was revised to include stabilizers (8577/
13 s). There was no evidence of inhibition of this revised matrix, either
in testing prior to the collaborative study or during the collaborative
study itself. All HEV samples prepared from stool were found to de-
monstrate instability. Interestingly, pre-treatment of the plasma-de-
rived strain used to prepare the WHO IS with detergent, followed by
lyophilization rendered the HEV unstable and showed similar de-
gradation kinetics to the stool samples when RNA content was de-
termined. This may reflect the quasi-enveloped form of HEV in blood
and plasma [17] and the membranes most likely act to protect the HEV
particles during the lyophilization process. Sample 8577/13 has not
been included in the composition of the final panel. The other panel
members showed 0-0.3 log10 loss of titre after storage at +20 °C,
compared to the normal storage temperature of −20 °C.
Stability studies demonstrated 0-0-3 log10 change in HEV RNA
concentration after 3 months of storage at +4 °C, and +20 to +26 °C,
compared with samples stored at<−80 °C. No loss of titre was ob-
served for samples stored at −20 °C (normal storage temperature). In
accordance with WHO policy, no unitage has been assigned to the panel
members, although the potencies and range, determined in the colla-
borative study are available to inform users of the panel performance.
The 1st International Reference Panel for Hepatitis E Virus RNA
Genotypes (code number 8578/13) was established by the WHO ECBS
in October 2015. The custodian laboratory is the Paul-Ehrlich-Institut.
The panel is not intended to replace the WHO IS for HEV RNA but is
intended to be used to ensure adequate detection of different HEV
genotypes and sub-genotypes in nucleic acid testing.
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